The overall goals of this grant have been and continue to be the elucidation of the pharmacokinetics and pharmacodynamics of drugs affecting the kidney. Whereas previously the focus was jointly on diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs), the current submission is solely for studies concerning the latter, accounting for a change in the title of the grant. Goals of the current application include: 1. Studies in man to assess the effect of short versus long duration of action NSAIDs on renal function in patients with mild to moderate renal insufficiency. Prior data from our laboratory indicated that short acting NSAIDs had no overall adverse effect on renal function because they allowed recovery of renal function within the dosing interval. Thus, long-acting NSAIDs could cause persistent decrements in renal function in susceptible patients. We wish to prospectively explore this issue, and link renal functional effects to the stereo-selective pharmacokinetics of ibuprofen (short-acting) and piroxicam (long-acting) or to a sustained release preparation of ibuprofen. 2. Studies to quantify in vivo in healthy man the pharmacokinetics of the enantiomers of ibuprofen and the chiral inversion of R- to S-ibuprofen. 3. To assess whether the S-enantiomer of arylpropionic NSAIDs is the active moiety in terms of renal PG inhibition, we will assess in healthy man the renal effects of R- compared to S-ketoprofen. Use of this compound will avoid the confounding effects of chiral inversion in interpreting the data. 4. Studies in patients with renal insufficiency to assess the potential clinical importance of a """"""""futile cycle"""""""" of elimination of arylpropionic NSAIDs via formation of acylglucuronide metabolites. To do so, we will use NSAIDs which do not undergo chiral inversion; namely, flurbiprofen and ketoprofen. 5. In vitro studies of the mechanisms of chiral inversion specifically addressing the relationship between in vivo inversion and the ability in vitro to form thioesters with acetyl CoA.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK037994-07
Application #
3237080
Study Section
Pharmacology A Study Section (PHRA)
Project Start
1986-03-01
Project End
1995-03-31
Budget Start
1992-04-01
Budget End
1993-03-31
Support Year
7
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Brater, D Craig (2011) Update in diuretic therapy: clinical pharmacology. Semin Nephrol 31:483-94
Bennett, Susan J; Lane, Kathleen A; Welch, Janet et al. (2005) Medication and dietary compliance beliefs in heart failure. West J Nurs Res 27:977-93; discussion 994-9
Shankar, Sudha S; Brater, D Craig (2003) Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 284:F11-21
Chalasani, N; Gorski, J C; Horlander Sr, J C et al. (2001) Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol 12:1010-6
Brater, D C; Chalasani, N; Gorski, J C et al. (2001) Effect of albumin-furosemide mixtures on response to furosemide in cirrhotic patients with ascites. Trans Am Clin Climatol Assoc 112:108-15; discussion 116
Bennett, S J; Perkins, S M; Lane, K A et al. (2001) Social support and health-related quality of life in chronic heart failure patients. Qual Life Res 10:671-82
Bennett, S J; Perkins, S M; Lane, K A et al. (2001) Reliability and validity of the compliance belief scales among patients with heart failure. Heart Lung 30:177-85
Masica, A L; Azie, N E; Brater, D C et al. (2000) Intravenous diltiazem and CYP3A-mediated metabolism. Br J Clin Pharmacol 50:273-6
Agarwal, R; Gorski, J C; Sundblad, K et al. (2000) Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol 11:1100-5
Grubb, N G; Rudy, D W; Brater, D C et al. (1999) Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination. Br J Clin Pharmacol 48:494-500

Showing the most recent 10 out of 37 publications